• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道移植相关微血管病的临床病理表现及治疗

Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy.

作者信息

Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, Sawa M, Murata M, Nishiwaki S, Oba T, Yanada M, Naoe T, Ichihashi R, Fujino M, Yamaguchi T, Morishita Y, Hirabayashi N, Kodera Y, Miyamura K

机构信息

Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya 466-8560, Japan.

出版信息

Bone Marrow Transplant. 2009 Jul;44(1):43-9. doi: 10.1038/bmt.2008.419. Epub 2009 Jan 12.

DOI:10.1038/bmt.2008.419
PMID:19139727
Abstract

Intestinal transplant-associated microangiopathy (i-TAM) is an important complication after allogeneic hematopoietic SCT. From 1997 to 2006, 87 of 886 patients with diarrhea after transplantation received colonoscopic biopsy. i-TAM, GVHD and CMV colitis were diagnosed histopathologically. The median duration from transplantation to the onset of diarrhea was 32 days (range: 9-130 days) and that from the onset of diarrhea to biopsy was 12 days (range: 0-74 days). The median maximal amount of diarrhea was 2 l/day (range: 130-5600 ml/day). Histopathological diagnosis included i-TAM (n=80), GVHD (n=26), CMV colitis (n=17) and nonspecific findings (n=2) with overlapping. Among 80 patients with i-TAM, abdominal pain was a major symptom, and only 11 patients fulfilled the proposed criteria for systemic TAM. Non-relapse mortality (NRM) among patients without resolution of diarrhea was 72% and i-TAM comprised 57% of NRM. NRM was 25% among patients without intensified immunosuppression, but was 52, 79 and 100% among those with intensified immunosuppression before diarrhea, after diarrhea, and before and after diarrhea, respectively. In conclusion, i-TAM is a major complication presenting massive refractory diarrhea and abdominal pain, which causes NRM. Avoiding intensified immunosuppression that damages vascular endothelium until the resolution of i-TAM may improve transplant outcome.

摘要

肠道移植相关微血管病(i-TAM)是异基因造血干细胞移植后的一种重要并发症。1997年至2006年,886例移植后腹泻患者中有87例接受了结肠镜活检。通过组织病理学诊断出i-TAM、移植物抗宿主病(GVHD)和巨细胞病毒(CMV)结肠炎。从移植到腹泻发作的中位持续时间为32天(范围:9 - 130天),从腹泻发作到活检的中位持续时间为12天(范围:0 - 74天)。腹泻的最大中位量为2升/天(范围:130 - 5600毫升/天)。组织病理学诊断包括i-TAM(n = 80)、GVHD(n = 26)、CMV结肠炎(n = 17)和非特异性发现(n = 2)且存在重叠。在80例i-TAM患者中,腹痛是主要症状,只有11例符合系统性TAM的拟定标准。腹泻未缓解患者的非复发死亡率(NRM)为72%,其中i-TAM占NRM的57%。未强化免疫抑制的患者NRM为25%,但在腹泻前、腹泻后以及腹泻前后均强化免疫抑制的患者中,NRM分别为52%、79%和100%。总之,i-TAM是一种主要并发症,表现为大量难治性腹泻和腹痛,可导致NRM。在i-TAM缓解之前避免损害血管内皮的强化免疫抑制可能会改善移植结局。

相似文献

1
Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy.肠道移植相关微血管病的临床病理表现及治疗
Bone Marrow Transplant. 2009 Jul;44(1):43-9. doi: 10.1038/bmt.2008.419. Epub 2009 Jan 12.
2
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.在患有移植相关微血管病或移植物抗宿主病相关肾功能不全的患者中,用达利珠单抗替代钙调神经磷酸酶抑制剂。
Bone Marrow Transplant. 2006 Sep;38(6):445-51. doi: 10.1038/sj.bmt.1705454.
3
Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants.
Bone Marrow Transplant. 2005 Dec;36(11):993-1000. doi: 10.1038/sj.bmt.1705160.
4
Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.外周血嗜酸性粒细胞增多对异基因外周血干细胞移植后的移植结局具有良好的预后影响。
Biol Blood Marrow Transplant. 2009 Apr;15(4):471-82. doi: 10.1016/j.bbmt.2009.01.003.
5
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.异基因干细胞移植后接受他克莫司治疗的患者的移植相关微血管病:危险因素及治疗反应
Biol Blood Marrow Transplant. 2007 Apr;13(4):469-77. doi: 10.1016/j.bbmt.2006.11.020. Epub 2007 Feb 8.
6
Study on the colonoscopic features of GVHD enteritis that developed after hematopoietic stem cell transplantation.造血干细胞移植后发生的移植物抗宿主病肠炎的结肠镜特征研究。
Hepatogastroenterology. 2007 Dec;54(80):2221-7.
7
Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation.减低强度脐带血移植后发生的肠道血栓性微血管病。
Bone Marrow Transplant. 2005 Sep;36(6):517-23. doi: 10.1038/sj.bmt.1705099.
8
Severe acute gastrointestinal graft-vs-host disease: an emerging surgical dilemma in contemporary cancer care.严重急性胃肠道移植物抗宿主病:当代癌症治疗中一个新出现的外科难题。
Arch Surg. 2008 Nov;143(11):1041-5; discussion 1046. doi: 10.1001/archsurg.143.11.1041.
9
Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.难治性白血病异基因造血干细胞移植中预防移植物抗宿主病的序贯强化预处理及预防性免疫抑制剂的减量
Biol Blood Marrow Transplant. 2009 Nov;15(11):1376-85. doi: 10.1016/j.bbmt.2009.06.017. Epub 2009 Aug 19.
10
Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.在急性髓系白血病患者接受不匹配、非亲属造血干细胞移植后,使用低剂量抗胸腺细胞球蛋白成功预防急性移植物抗宿主病。
Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17. doi: 10.1016/j.bbmt.2009.02.010. Epub 2009 Apr 9.

引用本文的文献

1
Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.间充质干细胞对异基因造血干细胞移植后特发性肺炎综合征的治疗作用
Int J Hematol. 2025 Jun 9. doi: 10.1007/s12185-025-04013-0.
2
Transplant-associated thrombotic microangiopathy in pediatrics: incidence, risk factors, therapeutic options, and outcome based on data from a single center.儿童移植相关血栓性微血管病:基于单中心数据的发病率、危险因素、治疗选择及预后
Front Oncol. 2024 Jul 10;14:1399696. doi: 10.3389/fonc.2024.1399696. eCollection 2024.
3
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.
纳武利尤单抗在儿童和成人移植相关血栓性微血管病患者中的安全性和疗效:真实世界经验。
Bone Marrow Transplant. 2024 Aug;59(8):1161-1168. doi: 10.1038/s41409-024-02305-3. Epub 2024 May 21.
4
Pathophysiology of acute graft-versus-host disease from the perspective of hemodynamics determined by dielectric analysis.从介电分析确定的血流动力学角度看急性移植物抗宿主病的病理生理学
World J Transplant. 2023 Dec 18;13(6):379-390. doi: 10.5500/wjt.v13.i6.379.
5
Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.同种异体造血干细胞移植中的移植相关性血栓性微血管病:现状。
Int J Mol Sci. 2023 Jan 6;24(2):1159. doi: 10.3390/ijms24021159.
6
Cerebral vascular injury in transplant-associated thrombotic microangiopathy.移植相关性血栓性微血管病中的脑血管损伤。
Blood Adv. 2022 Jul 26;6(14):4310-4319. doi: 10.1182/bloodadvances.2022007453.
7
Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults.成人急性移植物抗宿主病、BK 病毒出血性膀胱炎和年龄是移植相关血栓性微血管病的危险因素。
Blood Adv. 2022 Feb 22;6(4):1342-1349. doi: 10.1182/bloodadvances.2021004933.
8
[Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy].[移植相关血栓性微血管病的诊断与管理进展]
Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):693-699. doi: 10.3760/cma.j.issn.0253-2727.2021.08.018.
9
Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.内皮细胞功能障碍:异基因干细胞移植结局的关键决定因素。
Bone Marrow Transplant. 2021 Oct;56(10):2326-2335. doi: 10.1038/s41409-021-01390-y. Epub 2021 Jul 12.
10
[Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)].《移植相关血栓性微血管病诊断和管理中国专家共识(2021年版)》
Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):177-184. doi: 10.3760/cma.j.issn.0253-2727.2021.03.001.